Gilead’s former CCO to chair Memo board
Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors.
Mr Carter has had a long executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia.
He has more than 10 years of experience working in the virology field at US biotech major Gilead Sciences (Nasdaq: GILD), most recently as executive vice president (EVP) and chief commercial officer, where he oversaw more than $30 billion dollars of sales and contributed to multiple M&A transactions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze